Results 301 to 310 of about 125,484 (349)

Antimicrobial and Anti-Efflux Machinery of FDA-Approved Proton Pump Inhibitors and Vitamins Against <i>Klebsiella pneumoniae</i> and <i>Pseudomonas aeruginosa</i>. [PDF]

Microorganisms
Lutfi LL, Shaldam MA, Shaaban MI, Elshaer SL.   +3 more
europepmc   +1 more source

Proton pump inhibitors use and risk of type 2 diabetes mellitus: correlation analysis, prediction model construction, and key genes identification. [PDF]

Front Pharmacol
Liang C, Zhang Y.
europepmc   +1 more source

Economic evaluation of proton pump inhibitors in patients with gastro-oesophageal reflux disease: a systematic review. [PDF]

BMJ Open Gastroenterol
Tabaeian SP, Moeini S, Rezapour A, Afshari S, Souresrafil A, Barzegar M.   +5 more
europepmc   +1 more source

Approaches to Deprescribing Proton Pump Inhibitors in Clinical Practice: A Systematic Review. [PDF]

J Clin Med
Rossi A, Perrella L, Scotti S, Olmastroni E, Galimberti F, Ardoino I, Orlando V, Menditto E, Franchi C, Casula M.   +9 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Deprescribing proton pump inhibitors

Australian Journal of General Practice, 2022
Proton pump inhibitors (PPIs) are indicated for disorders including peptic ulcer disease and gastro-oesophageal reflux disease; however, they are often used for longer and at higher doses than recommended, or for indications that are not supported by evidence.The aim of this article is to outline evidence-based approaches to deprescribing PPIs.PPIs are
Turner, Justin P., Thompson, Wade, Reeve, Emily, Bell, J. Simon   +3 more
openaire   +4 more sources

Proton pump inhibitors and osteoporosis

Current Opinion in Rheumatology, 2016
Purpose of review The purpose of the review is to provide an update on recent advances in the evidence based on proton pump inhibitors (PPI) as a possible cause of osteoporosis and osteoporotic fractures. This review focuses, in particular, on new studies published in the last 18 months and a discussion of these findings and ...
Andersen, Bjarne Nesgaard, Johansen, Per Birger, Abrahamsen, Bo   +2 more
openaire   +3 more sources

Hypomagnesemia and proton-pump inhibitors

Expert Opinion on Drug Safety, 2013
Proton pump inhibitors (PPIs) have been linked to clinically symptomatic hypomagnesemia.We searched Medline database in all languages using 'proton-pump inhibitors, magnesium, hypomagnesemia and hypomagnesemic hypoparathyroidism' as search terms and other articles were identified through searches of the files of the authors and reference lists from ...
Laura Gasbarrone, Giovanni Minisola, Giuseppe Famularo   +2 more
openaire   +3 more sources

Pharmacogenomics of proton pump inhibitors

Pharmacogenomics, 2004
Proton pump inhibitors (PPIs), such as omeprazole, lansoprazole, rabeprazole, esomeprazole, and pantoprazole, are metabolized by cytochrome P450 isoenzyme 2C19 (CYP2C19) in the liver. There are genetic differences that affect the activity of this enzyme. The genotypes of CYP2C19 are classified into three groups: homozygous extensive metabolizer (homEM),
Naohito Shirai, Takashi Ishizaki, Takahisa Furuta, Mitsushige Sugimoto, Kyoichi Ohashi   +4 more
openaire   +3 more sources

Proton pump inhibitors [PDF]

British Dental Journal, 2010
Ursula Gotel nee Collignon, Janaka Karalliedde, Simon Clarke, Lakshman Delgoda Karalliedde   +3 more
openaire   +4 more sources